Sign in

David Hester

Managing Director and Senior Equity Research Analyst at Raymond James Financial Inc.

David Hester is a Managing Director and Senior Equity Research Analyst at Raymond James, specializing in the coverage of healthcare sector companies including major firms such as Merck, Abbott Laboratories, and Baxter International. Renowned for his rigorous analysis and investment recommendations, Hester has achieved consistent success rates above industry averages, earning recognition among top analysts on platforms like TipRanks with a strong record of positive returns on his stock calls. He began his career in equity research in the early 2000s, previously holding positions at firms such as Morgan Stanley before joining Raymond James in 2015. Hester holds FINRA Series 7, 63, 86, and 87 licenses, underscoring his professional credentials and compliance expertise within the investment industry.

David Hester's questions to SIMMONS FIRST NATIONAL (SFNC) leadership

Question · Q3 2025

David Hester with Raymond James inquired about Simmons First National Corporation's key strategic initiatives and top priorities following recent transformational actions, including the HTM restructuring and new leadership. He also asked about the company's loan growth outlook, opportunities, and the expected acceleration of growth, as well as the projected net interest margin trajectory over the next 12 months, considering various balance sheet dynamics.

Answer

President Jay Brogdon outlined a shift in focus to the business structure, emphasizing organic growth capabilities through talent acquisition and driving operational excellence and efficiency. He reiterated a commitment to consistent, strong risk-adjusted returns, projecting low single-digit loan growth but an increasingly positive outlook for pipeline and production. Brogdon highlighted a significant tailwind from nearly $3 billion in fixed-rate loans repricing over 24 months, yielding about 3.9%. CFO Daniel Hobbs and Brogdon discussed the 3.65%+ net interest margin outlook for Q4, noting the defensibility of the margin due to hedging actions and core balance sheet NIM growth. Hobbs stated the goal is to manage NIM within the 3.50-3.75% range through hedging.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts